VIR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Vir Biotechnology Inc (VIR) is not a strong buy for a beginner, long-term investor at this time. The company's financial performance is weak, hedge funds are selling, and there are no recent positive news catalysts. While technical indicators show some bullish signals, the absence of strong proprietary trading signals and the negative financial outlook make it prudent to hold off on investing in this stock for now.
The stock shows mixed technical signals. The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 65.867. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), suggesting a short-term uptrend. Key support and resistance levels are Pivot: 7.433, R1: 7.857, S1: 7.01, R2: 8.119, S2: 6.748.
Bullish moving averages indicate a short-term uptrend. Gross margin increased by 6.82% YoY in the latest quarter.
Hedge funds are selling significantly, with a 3690.48% increase in selling activity last quarter. Analysts have lowered price targets recently, with Barclays reducing the target to $24 and BofA reducing it to $13.
In Q3 2025, the company's revenue dropped to $240,000 (-89.92% YoY), net income fell to -$163.14M (-23.66% YoY), and EPS dropped to -1.17 (-25.00% YoY). However, gross margin increased to 104.58% (+6.82% YoY).
Barclays maintains an Overweight rating but lowered the price target from $31 to $24. BofA maintains a Buy rating but reduced the price target from $14 to $13. Analysts are cautious about the biotech sector's sustainability despite some positive trends.
